Organon acquires rights for Tofidence from Biogen
Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...
Biogen Inc. stock underperforms Monday when compared to competitors
Shares of Biogen Inc. BIIB shed 1.11% to $136.84 Monday, on what proved to be an all-around favorable trading session for the ...
pharmaphorum19h
Biogen signs $2.1 billion Parkinson's disease deal with Denali
Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion. Denali has been working on small ...